MediciNova To Get New Patent For Denibulin

(RTTNews) - MediciNova, Inc. (MNOV) and the Jasdaq Market of the Tokyo Stock Exchange Sunday said the U.S. Patent and Trademark Office has sanctioned its pending patent application which covers its MN-029, or denibulin di-hydrochloride.

The patent cover a compound, pharmaceutical composition and method of treating certain cell proliferation diseases, including solid tumors, based on denibulin di-hydrochloride. Once issued, the patent is anticipated to expire no earlier than July 2032.

"The new patent allows us more flexibility as we work to determine which solid tumors with high unmet medical needs are best to target in future development, " said Yuichi Iwaki, President and CEO of MediciNova, Inc.